
    
      A single-center, randomized, double-blind, placebo controlled, positive controlled, multiple
      dose, parallel group study will be conducted in healthy male and female subjects. Subjects
      will be randomized to one of 3 groups:

      Subjects in Group 1a (n=18) will be administered moxifloxacin placebo on Day 1, ampreloxetine
      placebo from Day 1 to Day 15, and moxifloxacin <Dose A> on Day 15.

      Subjects in Group 1b (n=18) will be administered a single oral dose of moxifloxacin <Dose A>
      on Day 1, ampreloxetine placebo from Day 1 to Day 15 and moxifloxacin placebo on Day 15.

      Subjects in Group 2 (n=36) will be administered moxifloxacin placebo on Day 1 and on Day 15,
      and ampreloxetine <Dose A> from Day 1 to Day 7, ampreloxetine <Dose B> from Day 8 to Day 14,
      and ampreloxetine placebo on Day 15.
    
  